Health ministry mulled compulsory licencing of rare disease drugs
NEW DELHI: The health ministry was actively mulling compulsory licensing, apart from price capping, of “orphan drugs” (for rare diseases), when the department of pharmaceuticals abruptly issued an order exempting…
Bristol-Myers Squibb buying Celgene in USD 74 bn deal
Bristol-Myers Squibb is buying Celgene in a cash-and-stock deal valued at about USD 74 billion. Shareholders of Celgene Corp, based in Summit, New Jersey, will receive one share of the…
Endeavour of govt is to provide affordable quality healthcare for all: Gowda
New Delhi: The government Thursday said it endeavours to provide affordable quality healthcare for all while also working to boost the domestic pharmaceutical sector through ‘Make in India’. As part…
Alembic Pharma gets USFDA nod for Parkinson’s treatment drug
New Delhi: Drug firm Alembic Pharmaceuticals Thursday said it has received approval from the US health regulator for Pramipexole Dihydrochloride extended-release tablets used for the treatment of Parkinson’s disease. The…
Biopharma Co Vyome gets Rs 154 crore from investors
New Delhi: Vyome Therapeutics, a biopharmaceutical firm focused on developing dermatology products, has raised $22 million (about Rs 154 crore) in a fresh round of funding led by Mumbai based…
Sun Pharma acquires Japan’s Pola Pharma
New Delhi: Drug major Sun Pharma Thursday said it has completed acquisition of Japan-based Pola Pharma to strengthen its presence in dermatology segment across the globe. The acquisition of 100…
Hetero Labs Limited acquires Tarbis Farma in Spain
Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, announced today that its European subsidiary Amarox Limited has acquired Tarbis Farma, S.L.U., a…
FSSAI to focus on enforcement of food standards in 2019
With new food quality standards in place, regulator FSSAI will focus on enforcing the regulations without impacting businesses, CEO Pawan Agarwal said Tuesday. During 2018, FSSAI accelerated the process of…
Controversies hurt Johnson & Johnson’s sales in India
Mumbai: US drug maker Johnson & Johnson, stung by controversies over its baby talc and medical devices, posted its first sales decline in India since at least 2002, according to…
Drug companies greet 2019 with U.S. price hikes
NEW YORK – Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world’s top-selling medicine, Humira, although the pace of…
